7 results match your criteria: "New York Blood Center Enterprise[Affiliation]"

Anti-D can occur in D-positive patients who inherit RHD genetic variants encoding partial D antigen expression, but unexpected anti-D is also found in the plasma of patients with sickle cell disease who have conventional RHD gene(s) and are transfused with units from Black donors. These anti-D are likely stimulated by variant Rh expressed on donor cells; however, patients with anti-D, regardless of cause, are transfused for a lifetime with D-negative (Rh-negative) blood. This results in significant increased use of Rh-negative units, especially for those requiring chronic transfusion, which can strain Rh-negative blood inventories.

View Article and Find Full Text PDF

Background: Red cell alloimmunization remains a challenge for individuals with sickle cell disease (SCD) and contributes to increased risk of hemolytic transfusion reactions and associated comorbidities. Despite prophylactic serological matching for ABO, Rh, and K, red cell alloimmunization persists, in part, due to a high frequency of variant RH alleles in patients with SCD and Black blood donors.

Study Design And Methods: We compared RH genotypes and rates of alloimmunization in 342 pediatric and young adult patients with SCD on chronic transfusion therapy exposed to >90,000 red cell units at five sites across the USA.

View Article and Find Full Text PDF

Background And Objectives: Under the ISBT, the Working Party (WP) for Red Cell Immunogenetics and Blood Group Terminology is charged with ratifying blood group systems, antigens and alleles. This report presents the outcomes from four WP business meetings, one located in Basel in 2019 and three held as virtual meetings during the COVID-19 pandemic in 2020 and 2021.

Materials And Methods: As in previous meetings, matters pertaining to blood group antigen nomenclature were discussed.

View Article and Find Full Text PDF
Article Synopsis
  • The study emphasizes the significance of minority RBC donors in meeting the transfusion needs of sickle cell disease patients and aims to validate a DNA-based screening method for sickle cell trait (SCT) instead of relying solely on a hemoglobin solubility assay.
  • The researchers conducted a validation process using both the traditional solubility assay and the new DNA test (HEA-HbS), confirming initial results but also encountering some discrepancies that were resolved through gene sequencing and HPLC analysis.
  • The conclusion highlights that the HEA-HbS DNA method correlates with HPLC results and presents a more efficient way to screen donors for SCT, facilitating better donor management and reducing the need for repeated testing.
View Article and Find Full Text PDF

Background: Reduced D antigen on red blood cells (RBCs) may be due to "partial" D phenotypes associated with loss of epitope(s) and risk for alloimmunization or "weak" D phenotypes that do not lack major epitopes with absence of clinical complications. Genotyping of samples with weak and discrepant D typing is recommended to guide transfusion and RhIG prophylaxis. The goal was to compare the impact of RHD genotyping on transfusion practice in two centers serving different populations.

View Article and Find Full Text PDF